The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. Keeping that in mind, here is one stock likely to meet or exceed Wall Street’s lofty expectations and two where consensus estimates seem disconnected from reality.
Two Stocks to Sell:
Wynn Resorts (WYNN)
Consensus Price Target: $139.83 (32% implied return)
Founded by the former Mirage Resorts CEO, Wynn Resorts (NASDAQ: WYNN) is a global developer and operator of high-end hotels and casinos, known for its luxurious properties and premium guest services.
Why Should You Sell WYNN?
- Annual revenue growth of 4.5% over the last two years was below our standards for the consumer discretionary sector
- Low free cash flow margin of 11.9% for the last two years gives it little breathing room, constraining its ability to self-fund growth or return capital to shareholders
- High net-debt-to-EBITDA ratio of 6× increases the risk of forced asset sales or dilutive financing if operational performance weakens
At $105.96 per share, Wynn Resorts trades at 20.3x forward P/E. Check out our free in-depth research report to learn more about why WYNN doesn’t pass our bar.
Neogen (NEOG)
Consensus Price Target: $12 (26.6% implied return)
Founded in 1981 and operating at the intersection of food safety and animal health, Neogen (NASDAQ: NEOG) develops and manufactures diagnostic tests and related products to detect dangerous substances in food and pharmaceuticals for animal health.
Why Do We Think NEOG Will Underperform?
- Products and services are facing significant end-market challenges during this cycle as sales have declined by 3.2% annually over the last two years
- Shrinking returns on capital from an already weak position reveal that neither previous nor ongoing investments are yielding the desired results
- EBITDA losses may force it to accept punitive lending terms or high-cost debt
Neogen’s stock price of $9.48 implies a valuation ratio of 35.6x forward P/E. Read our free research report to see why you should think twice about including NEOG in your portfolio.
One Stock to Buy:
Bowhead Specialty (BOW)
Consensus Price Target: $29.86 (25.5% implied return)
Named after the Arctic bowhead whale known for navigating challenging waters, Bowhead Specialty Holdings (NYSE: BOW) is a specialty insurance company that provides customized coverage for complex and high-risk commercial sectors.
Why Do We Love BOW?
- Strong 36.5% annualized net premiums earned expansion over the last two years shows it’s capturing market share this cycle
- Earnings growth has massively outpaced its peers over the last three years as its EPS has compounded at 28.9% annually
- Balance sheet strength has increased this cycle as its 30.9% annual book value per share growth over the last two years was exceptional
Bowhead Specialty is trading at $23.80 per share, or 1.5x forward P/B. Is now the right time to buy? See for yourself in our comprehensive research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month - FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.
